We have no plans to do so.
The Government is implementing all of the commitments in the 2014 Pharmaceutical Price Regulation Scheme (PPRS) on improving access to innovative medicines commensurate with the outcomes they offer patients. In addition, NHS England and the Association of the British Pharmaceutical Industry are pressing ahead with plans to maximise the benefits of the PPRS by improving access to and optimising the use of medicines to improve patient outcomes.
More generally, we have launched an ‘Innovative Medicines and Medical Technology Review’ of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for National Health Service patients to cost-effective new diagnostics, medicines and devices. The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.